Hydroxyethyl starch in severe sepsis: End of starch era?

Critical Care

Volumn 17, Issue 2, 2013, Pages

  Estrada, Carlos A ^a   Murugan, Raghavan ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; RINGER ACETATE; HETASTARCH DERIVATIVE; ISOTONIC SOLUTION;

ARTICLE; BLEEDING; BODY WEIGHT; CONTROLLED STUDY; CRYSTALLOID; DISEASE SEVERITY; FLUID RESUSCITATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SEPSIS; FEMALE; FLUID THERAPY; MALE;

FEMALE; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; ISOTONIC SOLUTIONS; MALE; SEPSIS;

EID: 84874960225     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12531     Document Type: Article

References (15)

1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, Reinhart K, Angus DC, Brun-Buisson C, Beale R, Calandra T, Dhainaut J-F, Gerlach H, Harvey M, Marini JJ, Marshall J, Ranieri M, Ramsay G, Sevransky J, Thompson BT, Townsend S, Vender JS, Zimmerman JL, Vincent J-L. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36:296-327. 10.1097/01.CCM.0000298158.12101.41, 18158437.
2. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, Forceville X, Feissel M, Hasselmann M, Heininger A, Van Aken H. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Crit Care 2012, 16:R94. 10.1186/cc11358, 3580640, 22624531.
3. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 2004, 350:2247-2256.
4. Westphal M, James MFM, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products--different effects. Anesthesiology 2009, 111:187-202. 10.1097/ALN.0b013e3181a7ec82, 19512862.
5. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffler M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008, 358:125-139. 10.1056/NEJMoa070716, 18184958.
6. Hartog CS, Reinhart K. CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients. Crit Care 2012, 16:454. 10.1186/cc11673, 23134688.
7. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard A-L, Fabritius ML, Mondrup F, Pott FC, Møller TP, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012, 367:124-134. 10.1056/NEJMoa1204242, 22738085.
8. National Heart, Lung, and Blood Institute (NHLBI) and Food and Drug Administration (FDA) Public Workshop: Risks and Benefits of Hydroxyethyl Starch Solutions. , http://www.nhlbi.nih.gov/meetings/workshops/Hydroxyethyl.htm
9. Claus RA, Sossdorf M, Hartog C. The effects of hydroxyethyl starch on cultured renal epithelial cells. Anesth Analg 2010, 110:300-301. 10.1213/ANE.0b013e3181ca03a4, 20081129.
10. Godier A, Durand M, Smadja D, Jeandel T, Emmerich J, Samama CM. Maize-or potato-derived hydroxyethyl starches: is there any thromboelastometric difference?. Acta Anaesthesiol Scand 2010, 54:1241-1247. 10.1111/j.1399-6576.2010.02306.x, 20840513.
11. Navickis RJ, Haynes GR, Wilkes MM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a meta-analysis of randomized trials. J Thorac Cardiovasc Surg 2012, 144:223-230. 10.1016/j.jtcvs.2012.04.009, 22578894.
12. Lehmann G, Marx G, Förster H. Bioequivalence comparison between hydroxyethyl starch 130/0.42/6: 1 and hydroxyethyl starch. 130/0.4/9: 1. Drugs R D 2007, 8:229-240. 10.2165/00126839-200708040-00003, 17596109.
13. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C, McGuinness S, Rajbhandari D, Taylor CB, Webb SAR. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012, 367:1901-1911. 10.1056/NEJMoa1209759, 23075127.
14. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent J-L, Moreno R. Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012. Crit Care Med 2013, 41:580-637. 10.1097/CCM.0b013e31827e83af, 23353941.
15. ClinicalTrials.gov Efficacy and Safety of Colloids Versus Crystalloids for Fluid Resuscitation in Critically Ill Patients. ClinicalTrials.gov., http://clinicaltrials.gov/ct2/show/NCT00318942